Companies › JSPR
Jasper Therapeutics Inc (JSPR)
Institutional ownership, SEC filings and insider activity
Sector: Healthcare & Pharma · SEC CIK 0001788028 · EDGAR filings · Updated 2026-07-23
Jasper Therapeutics Inc (JSPR) has reported institutional ownership of 56.5%, with 58 institutional managers holding positions valued at $13.9M per the latest 13F reporting period. SEC filings include an active non-reliance notice on previously issued financial statements (8-K Item 4.02), notice of delisting or failure to satisfy a continued listing rule (8-K Item 3.01), substantial-doubt (going concern) disclosure per the filings.
Filings this week (4)
- 2026-07-23 — Initial insider ownership filed (Form 3)
- 2026-07-22 — Insider transaction reported (Form 4)
- 2026-07-22 — Initial insider ownership filed (Form 3)
- 2026-07-22 — Initial insider ownership filed (Form 3)
Every filing links to the official SEC document. Real-time filing alerts for this company are available inside the app.
Latest updates
- 2026-07-20 — Insider transaction reported (Form 4)
- 2026-07-20 — Initial insider ownership filed (Form 3)
Institutional ownership overview
According to SEC 13F filings tracked by Sightfile, Jasper Therapeutics Inc has 58 institutional holders and institutional ownership of 56.5%.
Insider activity
Insiders reported 4 transactions (4 buys, 0 sells) across 4 reporting insiders, with a net reported value of $347.5K.
Data flags from SEC filings
Related companies
PARK DENTAL PARTNERS INC (PARK) · MOLECULAR PARTNERS AG (MOLN) · QT IMAGING HLDGS INC (QTI) · PASSAGE BIO INC COM NEW (PASG) · EDESA BIOTECH INC COM NEW (EDSA) · POLYPID LTD (PYPD)
See full history, cross-references and alerts on SightfileData sources: SEC EDGAR (filings, 13F, FTD), aggregated by Sightfile. Page updated 2026-07-23.